Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth

NCT03290092 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire Dijon as lead sponsor.

NCT NCT03290092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03290092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth
Lead sponsor
Centre Hospitalier Universitaire Dijon
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2017
Completion date
November 4, 2019
Enrollment
19 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pik3ca-related overgrowth